Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOS | P01100 | 2/20 | 0.50 |
| ▸ | JUN | P05412 | 2/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.37 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.37 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.37 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4287072 | 0.88 | NPC1 (0.45) | FOSJUNTP53MAPTALDH1A1 | |
| SCHEMBL4289803 | 0.85 | FOS (0.54) | FOSJUNNR1H4ALDH1A1LMNA | |
| SCHEMBL4279733 | 0.82 | FOS (0.54) | FOSJUNNR1H4TP53MAPT | |
| SCHEMBL4276431 | 0.81 | FOS (0.49) | FOSJUNNR1H4MAPTALDH1A1 | |
| SCHEMBL4279716 | 0.80 | FOS (0.63) | FOSJUNNR1H4MAPTALDH1A1 | |
| SCHEMBL4286099 | 0.79 | FOS (0.52) | FOSJUNNR1H4MAPTALDH1A1 | |
| SCHEMBL4276620 | 0.78 | JUN (0.81) | FOSJUNMAPTALDH1A1HTT | |
| SCHEMBL834768 | 0.77 | ATM (0.60) | NR1H4TP53ATMMAPTALDH1A1 | |
| SCHEMBL4289733 | 0.77 | FOS (0.48) | FOSJUNNR1H4TP53POLB | |
| SCHEMBL4279676 | 0.76 | FOS (0.52) | FOSJUNMAPTALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7314888-B1 | Compounds and medicinal use thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
| EP-1127869-A1 | NOVEL COMPOUNDS AND MEDICINAL USE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118169-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF | SP1, AP1G1, AP1M1 | FOS 63/4885JUN 20/4885NR1H4 2240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.